A Better Way to Catch Prostate Cancer—No Needles Required

When it comes to prostate cancer, timing is everything.

It’s one of the most common cancers in men—and also one of the most treatable. But only if it’s caught early.

For decades, the PSA (prostate-specific antigen) blood test has been the go-to screening method.

While it’s widely used, it’s also deeply flawed. PSA levels can rise for a variety of reasons—not just cancer—leading to false alarms, unnecessary biopsies, and a lot of stress for patients.

Now, a promising new development could change all of that.

Scientists have discovered a simple urine test that may not only detect prostate cancer earlier and more accurately than PSA, but also help determine how aggressive the cancer is—all without needles, pain, or invasive procedures.

And it’s powered by artificial intelligence.

In a new study published in Cancer Research, scientists used AI to comb through genetic data from thousands of prostate tumor cells.

They mapped out which genes were active and at what levels—effectively creating a detailed blueprint of prostate cancer at the molecular level.

From there, they identified a set of biomarkers—proteins linked to prostate cancer—that show up in the urine of men with the disease.

Researchers then tested these biomarkers in blood, tissue, and urine samples from nearly 2,000 patients.

The result? The urine-based biomarkers outperformed PSA in detecting prostate cancer. Not only that, they also accurately predicted disease severity, giving doctors a clearer picture of how serious the cancer might be.

“This approach outperforms the current blood tests based on PSA while keeping the advantages of being non-invasive, painless, and relatively cheap,” said lead author Martin Smelik.

PSA tests have long been a double-edged sword.

While they can detect prostate cancer, they also tend to flag benign conditions—like an enlarged or inflamed prostate—as potential cancer.

That often means false positives, followed by painful biopsies that may turn out to be unnecessary. For many men, this process creates anxiety and may even lead to overtreatment for cancers that might never have caused harm.

It’s a frustrating situation—especially when you consider that early-stage prostate cancer is one of the most curable cancers out there.

This new urine test offers a way to cut through the confusion and give men a clearer, more accurate answer.

The researchers used artificial intelligence to analyze mRNA activity—a snapshot of which genes are being turned “on” or “off” in cancer cells. By doing so, they identified specific protein markers that could be detected in urine.

Because the prostate is so close to the urinary tract, urine is an ideal fluid for collecting local cancer markers. It’s also non-invasive, making it easier for doctors to conduct regular screenings and track cancer progression over time.

This type of test could eventually reduce the number of unnecessary biopsies, help doctors catch cancer earlier, and even monitor how well treatments are working.

Dr. Milan Sheth, a board-certified oncologist who wasn’t involved in the study, praised the test’s accuracy and its potential to simplify prostate screening.

“Remarkably, the urinary biomarkers demonstrated exceptional diagnostic precision,” he said. “They were capable of distinguishing not only cancerous from non-cancer states, but also indicating disease severity.”

Dr. Ramkishen Narayanan, a urologic oncologist, noted that PSA has been the only prostate cancer biomarker for nearly 50 years.

“We are long overdue for additional tools,” he said. “And urine, being so close to the prostate, may hold the key.”

While the results are encouraging, large-scale clinical trials are still needed. Researchers are already planning a UK-wide study to validate the test and move it closer to clinical use.

If all goes well, this urine test could join or replace PSA as the new gold standard for prostate cancer screening.

And that’s a game-changer.

Prostate cancer is common—but when caught early, it’s highly treatable. This new AI-powered urine test could make screening easier, more accurate, and far less invasive for millions of men.

If you’re over 50, or have a family history of prostate cancer, talk to your doctor about screening.

And stay tuned—help could be on the way.

To catching cancer early,

Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team